Ensysce Biosciences Inc. has announced that enrollment has reached 50% of the targeted subjects for interim review in its pivotal Phase 3 clinical trial of PF614, a next-generation opioid candidate for severe acute pain. The PF614-301 trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of PF614 for the treatment of moderate to severe pain following abdominoplasty. Enrollment began in late December 2025 and is ongoing at three U.S. clinical sites. Interim results from the study have not yet been presented and will be available in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131092) on January 28, 2026, and is solely responsible for the information contained therein.